Lidocaine HCL Injection — Class II drug recall D-0594-2024
Ongoing recall by TAILSTORM HEALTH INC, reported 2024-07-17, distributed nationwide. Subpotent Drug: reduced efficacy for epinephrine
| Recall number | D-0594-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | TAILSTORM HEALTH INC, Chandler, AZ, United States |
| Recall initiated | 2024-07-03 |
| Classified | 2024-07-10 |
| Reported by FDA | 2024-07-17 |
| Distributed | Nationwide (US) |
| Quantity | 12,525 |
| Reason classes | potency |
| UPC / GTIN / UDI-DI | 00381483003802 |
| NDC | 81483-0038-00 |
| Lot numbers | 2311003 |
| Expiration dates | 2024-11-13 |
Product
Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,000, 10 ml Single Dose Vial, Rx only, Compounded drug by Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226, NDC 81483-0038-0, UPC 3 81483 00380 2
Reason for recall
Subpotent Drug: reduced efficacy for epinephrine
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0594-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.